S
CPRX

SignatureFD’s Catalyst Pharmaceutical CPRX Stock Holding History

SignatureFD’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.5K Buy
1,384
+895
+183% +$26.4K ﹤0.01% 1953
2026
Q1 		$12.1K Buy
489
+404
+475% +$9.63K ﹤0.01% 2422
2025
Q4 		$1.98K Hold
85
– – ﹤0.01% 2973
2025
Q3 		$1.68K Sell
85
-9
-10% -$185 ﹤0.01% 2995
2025
Q2 		$2.04K Sell
94
-72
-43% -$1.7K ﹤0.01% 2859
2025
Q1 		$4.03K Buy
166
+72
+77% +$1.62K ﹤0.01% 2680
2024
Q4 		$1.96K Sell
94
-11
-10% -$236 ﹤0.01% 2877
2024
Q3 		$2.09K Hold
105
– – ﹤0.01% 2825
2024
Q2 		$1.63K Hold
105
– – ﹤0.01% 2812
2024
Q1 		$1.67K Hold
105
– – ﹤0.01% 2849
2023
Q4 		$1.76K Hold
105
– – ﹤0.01% 2791
2023
Q3 		$1.23K Hold
105
– – ﹤0.01% 2893
2023
Q2 		$1.41K Hold
105
– – ﹤0.01% 2895
2023
Q1 		$1.74K Sell
105
-37
-26% -$610 ﹤0.01% 2843
2022
Q4 		$2.64K Buy
142
+37
+35% +$570 ﹤0.01% 2715
2022
Q3 		$1K Buy
105
+71
+209% +$841 ﹤0.01% 2932
2022
Q2 		$0 Buy
+34
New +$249 ﹤0.01% 3146
2014
Q3 		– Sell
-3,000
Closed -$8K – 738
2014
Q2 		$8K Buy
+3,000
New +$6.41K ﹤0.01% 488

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SignatureFD's CPRX Position: Q2 2026 in Review

SignatureFD increased its Catalyst Pharmaceutical (CPRX) stake by 183% in Q2 2026, buying an estimated $26.4K and bringing the position to 1,384 shares worth $43.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

SignatureFD first reported a position in CPRX in Q2 2014 and has held it in 18 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • SignatureFD held 1,384 shares of Catalyst Pharmaceutical worth $43.5K as of Q2 2026.
  • SignatureFD bought 895 Catalyst Pharmaceutical shares in Q2 2026, an estimated $26.4K.
  • Catalyst Pharmaceutical made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1953 holding.
  • SignatureFD first reported a position in Catalyst Pharmaceutical in Q2 2014 and has held it in 18 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.